Search

Your search keyword '"Kupcinskas L"' showing total 365 results
Start Over Author "Kupcinskas L"
365 results on '"Kupcinskas L"'

3. P778 Effectiveness and safety of a second-line rescue therapy for acute severe ulcerative colitis refractory to infliximab or ciclosporin (REASUC study)

Author

García, M J, primary, Riestra, S, additional, Amiot, A, additional, Julsgaard, M, additional, García de la Filia, I, additional, Calafat, M, additional, Aguas, M, additional, de la Peña, L, additional, Roig-Ramos, C, additional, Caballol, B, additional, Casanova, M J, additional, Farkas, K, additional, Boysen, T, additional, Bujanda, L, additional, Cuarán, C, additional, Dobru, D, additional, Fousekis, F, additional, Gargallo-Puyuelo, C J, additional, Savarino, E, additional, Calvet, X, additional, Huguet, J M, additional, Kupcinskas, L, additional, López-Cardona, J, additional, Raine, T, additional, van Oostrom, J, additional, Gisbert, J P, additional, and Chaparro, M, additional

Published
2023
Full Text
View/download PDF

4. Incidence and initial disease course of inflammatory bowel diseases in 2011 in Europe and Australia: Results of the 2011 ECCO-EpiCom inception cohort

Author

Vegh, Z., Burisch, J., Pedersen, N., Kaimakliotis, I., Duricova, D., Bortlik, M., Avnstrøm, S., Vinding, K. Kofod, Olsen, J., Nielsen, K.R., Katsanos, K.H., Tsianos, E.V., Lakatos, L., Schwartz, D., Odes, S., Lupinacci, G., De Padova, A., Jonaitis, L., Kupcinskas, L., Turcan, S., Tighineanu, O., Mihu, I., Barros, L.F., Magro, F., Lazar, D., Goldis, A., Fernandez, A., Hernandez, V., Niewiadomski, O., Bell, S., Langholz, E., Munkholm, P., and Lakatos, P.L.

Published
2014
Full Text
View/download PDF

5. Health-related quality of life improves during one year of medical and surgical treatment in a European population-based inception cohort of patients with Inflammatory Bowel Disease — An ECCO-EpiCom study

Author

Burisch, J., Weimers, P., Pedersen, N., Cukovic-Cavka, S., Vucelic, B., Kaimakliotis, I., Duricova, D., Bortlik, M., Shonová, O., Vind, I., Avnstrøm, S., Thorsgaard, N., Krabbe, S., Andersen, V., Dahlerup, J.F., Kjeldsen, J., Salupere, R., Olsen, J., Nielsen, K.R., Manninen, P., Collin, P., Katsanos, K.H., Tsianos, E.V., Ladefoged, K., Lakatos, L., Ragnarsson, G., Björnsson, E., Bailey, Y., O'Morain, C., Schwartz, D., Odes, S., Valpiani, D., Boni, M.C., Jonaitis, L., Kupcinskas, L., Turcan, S., Barros, L., Magro, F., Lazar, D., Goldis, A., Nikulina, I., Belousova, E., Fernandez, A., Sanroman, L., Almer, S., Zhulina, Y., Halfvarson, J., Arebi, N., Diggory, T., Sebastian, S., Lakatos, P.L., Langholz, E., and Munkholm, P.

Published
2014
Full Text
View/download PDF

6. Health care and patients' education in a European inflammatory bowel disease inception cohort: An ECCO-EpiCom study

Author

Burisch, J., Vegh, Z., Pedersen, N., Čuković-Čavka, S., Turk, N., Kaimakliotis, I., Duricova, D., Bortlik, M., Shonová, O., Thorsgaard, N., Krabbe, S., Andersen, V., Dahlerup, J.F., Kjeldsen, J., Salupere, R., Olsen, J., Nielsen, K.R., Manninen, P., Collin, P., Katsanos, K.H., Tsianos, E.V., Ladefoged, K., Ragnarsson, G., Björnsson, E., Bailey, Y., O'Morain, C., Schwartz, D., Odes, S., Politi, P., Santini, A., Kiudelis, G., Kupcinskas, L., Turcan, S., Magro, F., Barros, L., Lazar, D., Goldis, A., Nikulina, I., Belousova, E., Sanromán, L., Martinez-Ares, D., Almer, S., Zhulina, Y., Halfvarson, J., Arebi, N., Houston, Y., Sebastian, S., Langholz, E., Lakatos, P.L., and Munkholm, P.

Published
2014
Full Text
View/download PDF

8. Environmental factors in a population-based inception cohort of inflammatory bowel disease patients in Europe — An ECCO-EpiCom study

Author

Burisch, J., Pedersen, N., Cukovic-Cavka, S., Turk, N., Kaimakliotis, I., Duricova, D., Bortlik, M., Shonová, O., Vind, I., Avnstrøm, S., Thorsgaard, N., Krabbe, S., Andersen, V., Dahlerup, J.F., Kjeldsen, J., Salupere, R., Olsen, J., Nielsen, K.R., Manninen, P., Collin, P., Katsanos, K.H., Tsianos, E.V., Ladefoged, K., Lakatos, L., Ragnarsson, G., Björnsson, E., Bailey, Y., O'Morain, C., Schwartz, D., Odes, S., Giannotta, M., Girardin, G., Kiudelis, G., Kupcinskas, L., Turcan, S., Barros, L., Magro, F., Lazar, D., Goldis, A., Nikulina, I., Belousova, E., Martinez-Ares, D., Hernandez, V., Almer, S., Zhulina, Y., Halfvarson, J., Arebi, N., Tsai, H.H., Sebastian, S., Lakatos, P.L., Langholz, E., and Munkholm, P.

Published
2014
Full Text
View/download PDF

9. DOP019 Immunomodulators reduce the risk of surgery and hospitalisation in Crohn’s disease in a prospective European population-based inception cohort: the Epi-IBD cohort

Author

Burisch, J, Andersen, V, Čuković-Čavka, S, Lakatos, P L, DʼInca, R, Magro, F, Arebi, N, Kievit, L, Kaimakliotis, I, Valpiani, D, Katsanos, K H, Vegh, Z, Dahlerup, J F, Fumery, M, Pedersen, N, Halfvarson, J, Belousova, E, Nielsen, K R, Turcan, S, Ellul, P, Kupcinskas, L, Oksanen, P, Duricova, D, Giannotta, M, Goldis, A, Hernandez, V, Salupere, R, Odes, S, Langholz, E, and Munkholm, P

Published
2018
Full Text
View/download PDF

10. European Registry on Helicobacter pylori management (Hp-EuReg): patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21 533 patients

Author

Nyssen OP, Bordin D, Tepes B, Pérez-Aisa Á, Vaira D, Caldas M, Bujanda L, Castro-Fernandez M, Lerang F, Leja M, Rodrigo L, Rokkas T, Kupcinskas L, Pérez- Lasala J, Jonaitis L, Shvets O, Gasbarrini A, Simsek H, Axon ATR, Buzás G, Machado JC, Niv Y, Boyanova L, Goldis A, Lamy V, Tonkic A, Przytulski K, Beglinger C, Venerito M, Bytzer P, Capelle L, Milosavljević T, Milivojevic V, Veijola L, Molina-Infante J, Vologzhanina L, Fadeenko G, Ariño I, Fiorini G, Garre A, Garrido J, F Pérez C, Puig I, Heluwaert F, Megraud F, O'Morain C, Gisbert JP, Romano M, Universidad Autónoma de Madrid (UAM), AS Loginov Moscow Clinical Scientific Center [Moscow, Russian Federation], A.I. Yevdokimov Moscow State University of Medicine and Dentistry [Moscow, Russian Federation], AM DC Rogaska [Rogaska Slatina, Slovenia], Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC), University of Bologna/Università di Bologna, Universidad del Pais Vasco / Euskal Herriko Unibertsitatea [Espagne] (UPV/EHU), Centro de Investigación Biomédica en Red en el Área temática de Enfermedades Hepáticas y Digestivas (CIBERehd), Liver Unit, Clínica Universitaria, CIBER-EHD, Østfold Hospital, University of Latvia (LU), Universidad de Oviedo [Oviedo], Henry Dunant Hospital [Athens, Greece], Lithuanian University of Health Sciences [Kaunas, Lithuania], Hospital Universitario HM Sanchinarro [Madrid, Spain], Università cattolica del Sacro Cuore = Catholic University of the Sacred Heart [Roma] (Unicatt), Faculty of Medicine [Hacettepe University], Hacettepe University = Hacettepe Üniversitesi, Leeds General Infirmary (LGI), Leeds Teaching Hospitals NHS Trust, Ferencváros Health Centre [Budapest, Hungary], Faculdade de Medicina da Universidade do Porto (FMUP), Universidade do Porto = University of Porto, Tel Aviv University (TAU), Medical University of Sofia [Bulgarie], Timisoara Hospital [Timisoara, Romania], Centre Hospitalier Universitaire de Charleroi, University of Split, Medical Centre for Postgraduate Education [Warsaw, Poland], University Hospital Basel [Basel], Otto-von-Guericke-Universität Magdeburg = Otto-von-Guericke University [Magdeburg] (OVGU), Copenhagen University Hospital, Meander Medical Center [Amersfoort, Netherlands], University of Belgrade [Belgrade], Herttoniemi Hospital [Helsinki, Finland], San Pedro de Alcantara Hospital [Cáceres, Espagne], Gastrocentr [Perm, Russian Federation], Digestive Ukrainian Academy of Medical Sciences [Kyiv, Ukraine], Hospital Clínico Universitario 'Lozano Blesa' [Zaragoza, Spain], Althaia Xarxa Assistencial Universitària de Manresa [Manresa, Spain], Universitat de Vic-Universitat Central de Catalunya [Manresa, Spain] (UVicUCC), Complejo Hospitalario Universitario de Santiago de Compostela [Saint-Jacques-de-Compostelle, Espagne] (CHUS), Centre Hospitalier Annecy-Genevois [Saint-Julien-en-Genevois], Physiopathologie du cancer du foie, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Pellegrin, CHU Bordeaux [Bordeaux]-Groupe hospitalier Pellegrin, Trinity College Dublin, Hp-EuReg Investigators: Jen Hinojosa, Inmaculada Santaella, Nuria Fernandez Moreno, Ilaria Maria Saracino, Horacio Alonso Galán, Almudena Durán, Jennifer Fernandez Pacheco, Miroslav Vujasinovic, Rinaldo Pellicano Molinette, Zdenko Kikec, Pedro-Luis Gonzalez Cordero, Maia Donday, Polona Lampic, Vid Leban, Aleksander Gruncic Krajnc, Natasa Brglez Jurecic, Galyna Dmytrivna Fadieienko, Lorena Lee, Irene V Barbado, Alfredo José Lucendo, Alfredo José Lucendo, Jesus Barrio RIo Hortega, Tatiana Alekseevna Ilchishina, Irina Voynovan, Luis Ignacio Fernández-Salazar, Jose María Huguet, Pilar Canelles, Aiman Silkanovna Sarsenbaeva, Ines Modolell Consorci, Pedro Almela, Marina Roldán Lafuente, Josep Maria Botargues, Miguel Areia, Luís Elvas, Susana Isabel Alves, Daniel Brito, Ana Teresa Cadime, Sandra Lúcia Madeira Saraiva, Charalampos Tzathas, Vassiliki Ntouli, Alicia C Marin, Cem Simsek, Alba Rocco, Juan Antonio Ortuño, Tommaso Di Maira, Sotirios D Georgopoulos, Stephan Brackmann, Vendel Kristensen Lovisenberg, Blas Jose Gomez-Rodriguez, Perminder Singh Phull, Sergey Alekseyevich, Monica Perona, Rustam Abdulkhakov, Deirdre McNamara, Sinead M Smith, Denise Elizabeth Brennan, Marina Fedorovna Osipenko, Cristobal de la Coba, Pilar Varela, Maria Anatolyevna Livzan, Oleg V Zaytsev, Vladislav Vladimirovich Tsukanov, Alexander Viktorovich Vasyutin, Olga Sergeevna Amelchugova, Spiros Michopoulus, Sergey Gennadievich Burkov, Dan Dumitrascu, Bogdan Ianosi, Ingrid Prytz Berset, Rafael Ruiz-Zorrilla Lopez, Charo Antón, Anne Courillon-Mallet, Natasa Brglez Jurecic, Judith Gomez-Camarero, Manuel Jimenez-Moreno, Ahmet Uygun, Ian Leonard Phillip Beales, Alain Huerta-Madrigal, Javier Alcedo, Mercè Barenys, Francesco Franceschi, Jean-Charles Delchier, Liliana Silvia Pozzati, Monika Augustyn, Maja Seruga, Miriam Hiestand, Patric Mosler, Zaza Beniashvili, Doron Boltin, Hubert Louis, Ramon Pajares, Natalia Valerievna Zakharova, Natalia Nikolaevna Dekhnich, Victor Asparuhov Kamburov, Maria Pina Dore, Lorena Sancho, Oscar Núñez, Katrine Dvergsnes Sørlandet, Peter Malfertheiner, Ana Campillo, Miguel Fernandez-Bermejo, Manuel Domínguez-Cajal, José Luis Domínguez Jiménez, Alicia Algaba, Fernando Bermejo, Borislav Vladimirov, László Czakó, Teresa Angueira, Eduardo Iyo, Ekaterina Yuryevna, Larissa Tarasova, Ludmila Grigorieva, Judith Millastre, Aldis Pukitis, Valeriy Kryvy, Roald Torp, Albert Tomàs, Edurne Amorena, Fermin Estremera, Rossen Nikolov, Asghar Quasim, Yury Aleksandrovich Kucheryavyy, Natalia Baryshnikova, Xavier Calvet, Ariadna Figuerola, Marco Romano, Antonietta Gerarda Gravina, Oscar Núñez, Fazia Mana, Pilar Sánchez-Pobre, Zoya Spassova, Jesús M González-Santiago, Ricardo Marcos-Pinto, F Wolfhagen, Svetlana Cui, Ivonne Leeuwenburgh, Driffa Moussata, Adi Lahat-Zok, Sergii Hryhorovych, Rasmus Goll, Tatyana Vasilyevna, Juris Pokrotnieks, Philippe Émile, Nadiya Byelyayeva, Marta Lozano, Mette Wildner-Christensen, Bengt Odman, Yana Valerieva, Alenka Forte, Antonio Cuadrado, Patrice Pienkowski, Ilze Kikuste, Dag Arne Lihaug Hoff, Jane Moeller Hansen, Konrads Funka, Alla Kononova, Sergey Kolbasnikov, Michael Selgrad, Jolanta Sumskiene, Jonathan Hirsch, Francisco Javier Zozaya Larequi, Alain C Burette, Nora Dancs Petz-Aladar, Janne Rajala Herttoniemi, Christina Reimer, Diogo Libanio, Pedro Pimentel-Nunes, Ivailo Evstatiev, Juozas Kupcinskas, Mikhail Butov, Peter Mensink, T Tang, Andrey Yurevich Baranovsky, Natalya Marchenko, Boris Bastens, Lyudmila Mateva, Dominique Lamarque, Leonardo Henry, Mario Ribeiro, M Ter Borg, Alexander C Ford, Enrique Medina, Manuel Rodriguez-Tellez, Francisco José Rancel, Elisa Martin, Carolina Torres Gonzalez, Lissa Maria Franco, Angel Lanas, Pilar Canelles, Noelia Alcaide, Bruno Richard-Molard, Megraud, Francis, Nyssen O.P., Bordin D., Tepes B., Perez-Aisa A., Vaira D., Caldas M., Bujanda L., Castro-Fernandez M., Lerang F., Leja M., Rodrigo L., Rokkas T., Kupcinskas L., Perez-Lasala J., Jonaitis L., Shvets O., Gasbarrini A., Simsek H., Axon A.T.R., Buzas G., Machado J.C., Niv Y., Boyanova L., Goldis A., Lamy V., Tonkic A., Przytulski K., Beglinger C., Venerito M., Bytzer P., Capelle L., Milosavljevic T., Milivojevic V., Veijola L., Molina-Infante J., Vologzhanina L., Fadeenko G., Arino I., Fiorini G., Garre A., Garrido J., F Perez C., Puig I., Heluwaert F., Megraud F., O'Morain C., Gisbert J.P., Universidad Autonoma de Madrid (UAM), University of Bologna, Università cattolica del Sacro Cuore [Roma] (Unicatt), Universidade do Porto, Tel Aviv University [Tel Aviv], Otto-von-Guericke University [Magdeburg] (OVGU), Nyssen, Op, Bordin, D, Tepes, B, Pérez-Aisa, Á, Vaira, D, Caldas, M, Bujanda, L, Castro-Fernandez, M, Lerang, F, Leja, M, Rodrigo, L, Rokkas, T, Kupcinskas, L, Pérez- Lasala, J, Jonaitis, L, Shvets, O, Gasbarrini, A, Simsek, H, Axon, Atr, Buzás, G, Machado, Jc, Niv, Y, Boyanova, L, Goldis, A, Lamy, V, Tonkic, A, Przytulski, K, Beglinger, C, Venerito, M, Bytzer, P, Capelle, L, Milosavljević, T, Milivojevic, V, Veijola, L, Molina-Infante, J, Vologzhanina, L, Fadeenko, G, Ariño, I, Fiorini, G, Garre, A, Garrido, J, F Pérez, C, Puig, I, Heluwaert, F, Megraud, F, O'Morain, C, Gisbert, Jp, and Romano, M

Subjects
Male, Registrie, Proton Pump Inhibitor, Practice Patterns, 0302 clinical medicine, Clarithromycin, Prospective Studies, Registries, Practice Patterns, Physicians', [SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, biology, Gastroenterology, Middle Aged, Anti-Bacterial Agents, 3. Good health, Europe, 030220 oncology & carcinogenesis, Combination, 030211 gastroenterology & hepatology, Drug Therapy, Combination, Female, medicine.drug, Human, Adult, medicine.medical_specialty, TRIPLE THERAPY, QUADRUPLE THERAPY, CONSENSUS, INFECTION, METAANALYSIS, CLARITHROMYCIN, GUIDELINES, RESISTANCE, ARTICLE, Settore MED/12 - GASTROENTEROLOGIA, First line, Helicobacter Infections, 03 medical and health sciences, Drug Therapy, Internal medicine, Anti-Bacterial Agent, medicine, Humans, Medical prescription, Adverse effect, Aged, Physicians', Helicobacter pylori, business.industry, helicobacter pylori - treatment, Proton Pump Inhibitors, Amoxicillin, biology.organism_classification, Metronidazole, Prospective Studie, Concomitant, helicobacter pylori, business, Helicobacter Infection, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

ObjectiveThe best approach for Helicobacter pylori management remains unclear. An audit process is essential to ensure clinical practice is aligned with best standards of care.DesignInternational multicentre prospective non-interventional registry starting in 2013 aimed to evaluate the decisions and outcomes in H. pylori management by European gastroenterologists. Patients were registered in an e-CRF by AEG-REDCap. Variables included demographics, previous eradication attempts, prescribed treatment, adverse events and outcomes. Data monitoring was performed to ensure data quality. Time-trend and geographical analyses were performed.Results30 394 patients from 27 European countries were evaluated and 21 533 (78%) first-line empirical H. pylori treatments were included for analysis. Pretreatment resistance rates were 23% to clarithromycin, 32% to metronidazole and 13% to both. Triple therapy with amoxicillin and clarithromycin was most commonly prescribed (39%), achieving 81.5% modified intention-to-treat eradication rate. Over 90% eradication was obtained only with 10-day bismuth quadruple or 14-day concomitant treatments. Longer treatment duration, higher acid inhibition and compliance were associated with higher eradication rates. Time-trend analysis showed a region-dependent shift in prescriptions including abandoning triple therapies, using higher acid-inhibition and longer treatments, which was associated with an overall effectiveness increase (84%–90%).ConclusionManagement of H. pylori infection by European gastroenterologists is heterogeneous, suboptimal and discrepant with current recommendations. Only quadruple therapies lasting at least 10 days are able to achieve over 90% eradication rates. European recommendations are being slowly and heterogeneously incorporated into routine clinical practice, which was associated with a corresponding increase in effectiveness.

Published
2020

11. Room for Improvement in the Treatment of Helicobacter pylori Infection: Lessons from the European Registry on H. pylori Management (Hp-EuReg)

Author

Nyssen, O. P., Vaira, D., Tepes, B., Kupcinskas, L., Bordin, D., Perez-Aisa, A., Gasbarrini, Antonio, Castro-Fernandez, M., Bujanda, L., Garre, A., Lucendo, A., Vologzhanina, L., Jurecic, N. B., Rodrigo-Saez, L., Huguet, J. M., Voynovan, I., Perez-Lasala, J., Romero, P. M., Vujasinovic, M., Abdulkhakov, R., Barrio, J., Fernandez-Salazar, L., Megraud, F., O'Morain, C., Gisbert, J. P., Gasbarrini A. (ORCID:0000-0002-7278-4823), Nyssen, O. P., Vaira, D., Tepes, B., Kupcinskas, L., Bordin, D., Perez-Aisa, A., Gasbarrini, Antonio, Castro-Fernandez, M., Bujanda, L., Garre, A., Lucendo, A., Vologzhanina, L., Jurecic, N. B., Rodrigo-Saez, L., Huguet, J. M., Voynovan, I., Perez-Lasala, J., Romero, P. M., Vujasinovic, M., Abdulkhakov, R., Barrio, J., Fernandez-Salazar, L., Megraud, F., O'Morain, C., Gisbert, J. P., and Gasbarrini A. (ORCID:0000-0002-7278-4823)

Abstract

Background: Managing Helicobacter pylori infection requires constant decision making, and each decision is open to possible errors. Aim: The aim was to evaluate common mistakes in the eradication of H. pylori, based on the "European Registry on Helicobacter pylori management". Methods: European Registry on Helicobacter pylori management is an international multicentre prospective noninterventional registry evaluating the decisions and outcomes of H. pylori management by European gastroenterologists in routine clinical practice. Results: Countries recruiting more than 1000 patients were included (26,340 patients). The most common mistakes (percentages) were: (1) To use the standard triple therapy where it is ineffective (46%). (2) To prescribe eradication therapy for only 7 to 10 days (69%). (3) To use a low dose of proton pump inhibitors (48%). (4) In patients allergic to penicillin, to prescribe always a triple therapy with clarithromycin and metronidazole (38%). (5) To repeat certain antibiotics after eradication failure (>15%). (6) Failing to consider the importance of compliance with treatment (2%). (7) Not to check the eradication success (6%). Time-trend analyses showed progressive greater compliance with current clinical guidelines. Conclusion: The management of H. pylori infection by some European gastroenterologists is heterogeneous, frequently suboptimal and discrepant with current recommendations. Clinical practice is constantly adapting to updated recommendations, although this shift is delayed and slow.

Published
2022

13. P695 The risk of proximal disease extension in patients with limited ulcerative colitis in a prospective European population-based inception cohort – the ECCO-EpiCom cohort

Author

Burisch, J., Halfvarson, J., Kupcinskas, L., Hernandez, V., Kaimakliotis, I., Valpiani, D., Pedersen, N., Duricova, D., Kievit, L., Dahlerup, J.F., Fumery, M., Salupere, R., Arebi, N., Nielsen, K.R., Giannotta, M., Oksanen, P., Katsanos, K.H., Vegh, Z., Ellul, P., Schwartz, D., Čuković-Čavka, S., DʼIncà, R., Turcan, S., Magro, F., Goldis, A., Langholz, E., Lakatos, P.L., and Munkholm, P.

Published
2017
Full Text
View/download PDF

14. P727 Change in Crohnʼs disease behavior in a prospective European population-based inception cohort – the ECCO-EpiCom cohort

Author

Burisch, J., Halfvarson, J., Kupcinskas, L., Hernandez, V., Kaimakliotis, I., Valpiani, D., Pedersen, N., Duricova, D., Kievit, L., Dahlerup, J.F., Fumery, M., Salupere, R., Arebi, N., Nielsen, K.R., Giannotta, M., Oksanen, P., Katsanos, K.H., Vegh, Z., Ellul, P., Schwartz, D., Čuković-Čavka, S., DʼIncà, R., Turcan, S., Magro, F., Goldis, A., Langholz, E., Lakatos, P.L., and Munkholm, P.

Published
2017
Full Text
View/download PDF

15. P694 Disease course during the first five years following diagnosis in a prospective European population-based inception cohort – the ECCO-EpiCom cohort

Author

Burisch, J., Halfvarson, J., Kupcinskas, L., Hernandez, V., Kaimakliotis, I., Valpiani, D., Pedersen, N., Duricova, D., Kievit, L., Dahlerup, J.F., Fumery, M., Salupere, R., Arebi, N., Nielsen, K.R., Giannotta, M., Oksanen, P., Katsanos, K.H., Vegh, Z., Ellul, P., Schwartz, D., Čuković-Čavka, S., DʼIncà, R., Turcan, S., Magro, F., Goldis, A., Langholz, E., Lakatos, P.L., and Munkholm, P.

Published
2017
Full Text
View/download PDF

17. Association of adverse perinatal outcomes of intrahepatic cholestasis of pregnancy with biochemical markers: Results of aggregate and individual patient data meta-analyses

Author

Ovadia, C, Seed, P, Sklavounos, A, Geenes, V, Di Illio, C, Chambers, J, Kohari, K, Bacq, Y, Bozkurt, N, Brun-Furrer, R, Bull, L, Estiu, M, Grymowicz, M, Gunaydin, B, Hague, W, Haslinger, C, Hu, Y, Kawakita, T, Kebapcilar, A, Kebapcilar, L, Kondrackiene, J, Koster, M, Kowalska-Kanka, A, Kupcinskas, L, Lee, R, Locatelli, A, Macias, R, Marschall, H, Oudijk, M, Raz, Y, Rimon, E, Shan, D, Shao, Y, Tribe, R, Tripodi, V, Abide, C, Yenidede, I, Thornton, J, Chappell, L, Williamson, C, Ovadia C., Seed P. T., Sklavounos A., Geenes V., Di Illio C., Chambers J., Kohari K., Bacq Y., Bozkurt N., Brun-Furrer R., Bull L., Estiu M. C., Grymowicz M., Gunaydin B., Hague W. M., Haslinger C., Hu Y., Kawakita T., Kebapcilar A. G., Kebapcilar L., Kondrackiene J., Koster M. P. H., Kowalska-Kanka A., Kupcinskas L., Lee R. H., Locatelli A., Macias R. I. R., Marschall H. -U., Oudijk M. A., Raz Y., Rimon E., Shan D., Shao Y., Tribe R., Tripodi V., Abide C. Y., Yenidede I., Thornton J. G., Chappell L. C., Williamson C., Ovadia, C, Seed, P, Sklavounos, A, Geenes, V, Di Illio, C, Chambers, J, Kohari, K, Bacq, Y, Bozkurt, N, Brun-Furrer, R, Bull, L, Estiu, M, Grymowicz, M, Gunaydin, B, Hague, W, Haslinger, C, Hu, Y, Kawakita, T, Kebapcilar, A, Kebapcilar, L, Kondrackiene, J, Koster, M, Kowalska-Kanka, A, Kupcinskas, L, Lee, R, Locatelli, A, Macias, R, Marschall, H, Oudijk, M, Raz, Y, Rimon, E, Shan, D, Shao, Y, Tribe, R, Tripodi, V, Abide, C, Yenidede, I, Thornton, J, Chappell, L, Williamson, C, Ovadia C., Seed P. T., Sklavounos A., Geenes V., Di Illio C., Chambers J., Kohari K., Bacq Y., Bozkurt N., Brun-Furrer R., Bull L., Estiu M. C., Grymowicz M., Gunaydin B., Hague W. M., Haslinger C., Hu Y., Kawakita T., Kebapcilar A. G., Kebapcilar L., Kondrackiene J., Koster M. P. H., Kowalska-Kanka A., Kupcinskas L., Lee R. H., Locatelli A., Macias R. I. R., Marschall H. -U., Oudijk M. A., Raz Y., Rimon E., Shan D., Shao Y., Tribe R., Tripodi V., Abide C. Y., Yenidede I., Thornton J. G., Chappell L. C., and Williamson C.

Published
2019

18. Room for Improvement in the Treatment of Helicobacter pylori Infection: Lessons from the European Registry on H. pylori Management (Hp-EuReg)

Author

Nyssen O. P., Vaira D., Tepes B., Kupcinskas L., Bordin D., Perez-Aisa A., Gasbarrini A., Castro-Fernandez M., Bujanda L., Garre A., Lucendo A. J., Vologzhanina L., Jurecic N. B., Rodrigo-Saez L., Huguet J. M., Voynovan I., Perez-Lasala J., Romero P. M., Vujasinovic M., Abdulkhakov R., Barrio J., Fernandez-Salazar L., Megraud F., O'Morain C., Gisbert J. P., Ilchishina T., Arino I., Zaytsev O., Perona M., Sarsenbaeva A. S., Ortuno J., Alekseenko S., Dominguez-Cajal M., Rodriguez B. J. G., Notari P. A., Pellicano R., Consorci I. M., Nardone G., Bote J. M. B. -A., Nunez O., Gomez-Camarero J., Guadix J. H., Fiorini G., Jonaitis L., Galan H. A., Ferrer L., Molina-Infante J., Kikec Z., Alcaide N., Lanas A., Sant'Orsola V. C., Medina-Chulia E., Canelles P., Santos-Fernandez J., Velayos B., Di Maira T., Lafuente M. R., Moreno M. J., Dekhnich N. N., Varela P., de la Coba C., Osipenko M. F., Lopez R. R. -Z., Huerta-Madrigal A., Livzan M. A., Pozzati L. S., Iyo E., Amelchugova O. S., Vasyutin A. V., Tsukanov V. V., Barenys M., Burkov S. G., Gravina A. G., Romano M., Bakulina N. V., Fernandez-Bermejo M., Alcedo J., Franceschi F., Campillo A., Seruga M., Villarroya R. P., Mego M., Dore M. P., Tito L., Gmez B., Jimenez J. L. D., Bermejo F., Algaba A., Belousova L. N., Plotnikova E. Y., Calvet X., Figuerola A., Tarasova L., Grigorieva L., Amorena E., Estremera F., Sanchez-Pobre P., Millastre J., Tomas A., Baryshnikova N., Kucheryavyy Y. A., Kononova A., Bakulin I., Cerezo F. J. M., Venciene R., Zhestkova T. V., Rocco A., Gonzalez Santiago J. M., Nyssen, O. P., Vaira, D., Tepes, B., Kupcinskas, L., Bordin, D., Perez-Aisa, A., Gasbarrini, A., Castro-Fernandez, M., Bujanda, L., Garre, A., Lucendo, A. J., Vologzhanina, L., Jurecic, N. B., Rodrigo-Saez, L., Huguet, J. M., Voynovan, I., Perez-Lasala, J., Romero, P. M., Vujasinovic, M., Abdulkhakov, R., Barrio, J., Fernandez-Salazar, L., Megraud, F., O'Morain, C., Gisbert, J. P., Ilchishina, T., Arino, I., Zaytsev, O., Perona, M., Sarsenbaeva, A. S., Ortuno, J., Alekseenko, S., Dominguez-Cajal, M., Rodriguez, B. J. G., Notari, P. A., Pellicano, R., Consorci, I. M., Nardone, G., Bote, J. M. B. -A., Nunez, O., Gomez-Camarero, J., Guadix, J. H., Fiorini, G., Jonaitis, L., Galan, H. A., Ferrer, L., Molina-Infante, J., Kikec, Z., Alcaide, N., Lanas, A., Sant'Orsola, V. C., Medina-Chulia, E., Canelles, P., Santos-Fernandez, J., Velayos, B., Di Maira, T., Lafuente, M. R., Moreno, M. J., Dekhnich, N. N., Varela, P., de la Coba, C., Osipenko, M. F., Lopez, R. R. -Z., Huerta-Madrigal, A., Livzan, M. A., Pozzati, L. S., Iyo, E., Amelchugova, O. S., Vasyutin, A. V., Tsukanov, V. V., Barenys, M., Burkov, S. G., Gravina, A. G., Romano, M., Bakulina, N. V., Fernandez-Bermejo, M., Alcedo, J., Franceschi, F., Campillo, A., Seruga, M., Villarroya, R. P., Mego, M., Dore, M. P., Tito, L., Gmez, B., Jimenez, J. L. D., Bermejo, F., Algaba, A., Belousova, L. N., Plotnikova, E. Y., Calvet, X., Figuerola, A., Tarasova, L., Grigorieva, L., Amorena, E., Estremera, F., Sanchez-Pobre, P., Millastre, J., Tomas, A., Baryshnikova, N., Kucheryavyy, Y. A., Kononova, A., Bakulin, I., Cerezo, F. J. M., Venciene, R., Zhestkova, T. V., Rocco, A., Gonzalez Santiago, J. M., Lucendo, A., and the Hp-EuReg, Investigator

Subjects
Registrie, medicine.medical_specialty, Proton Pump Inhibitor, medicine.drug_class, Settore MED/12 - GASTROENTEROLOGIA, Antibiotics, MEDLINE, Helicobacter Infections, 03 medical and health sciences, 0302 clinical medicine, Pharmacotherapy, Drug Therapy, Clarithromycin, Internal medicine, Metronidazole, Anti-Bacterial Agent, bismuth, medicine, non-bismuth, Humans, Prospective Studies, Registries, Disease management (health), levofloxacin, biology, Helicobacter pylori, business.industry, mistake, Gastroenterology, Amoxicillin, Proton Pump Inhibitors, biology.organism_classification, error, Anti-Bacterial Agents, Penicillin, Prospective Studie, 030220 oncology & carcinogenesis, Combination, 030211 gastroenterology & hepatology, Drug Therapy, Combination, business, Helicobacter Infection, H. pylori, medicine.drug, Human
Abstract

BACKGROUND: Managing Helicobacter pylori infection requires constant decision making, and each decision is open to possible errors. AIM: The aim was to evaluate common mistakes in the eradication of H. pylori, based on the "European Registry on Helicobacter pylori management". METHODS: European Registry on Helicobacter pylori management is an international multicentre prospective noninterventional registry evaluating the decisions and outcomes of H. pylori management by European gastroenterologists in routine clinical practice. RESULTS: Countries recruiting more than 1000 patients were included (26,340 patients). The most common mistakes (percentages) were: (1) To use the standard triple therapy where it is ineffective (46%). (2) To prescribe eradication therapy for only 7 to 10 days (69%). (3) To use a low dose of proton pump inhibitors (48%). (4) In patients allergic to penicillin, to prescribe always a triple therapy with clarithromycin and metronidazole (38%). (5) To repeat certain antibiotics after eradication failure (>15%). (6) Failing to consider the importance of compliance with treatment (2%). (7) Not to check the eradication success (6%). Time-trend analyses showed progressive greater compliance with current clinical guidelines. CONCLUSION: The management of H. pylori infection by some European gastroenterologists is heterogeneous, frequently suboptimal and discrepant with current recommendations. Clinical practice is constantly adapting to updated recommendations, although this shift is delayed and slow.

Published
2020

20. A placebo-controlled randomised trial of budesonide for primary biliary cholangitis following an insufficient response to UDCA

Author

Hirschfield, G.M, Beuers, U., Kupcinskas, L., Ott, P., Bergquist, A., Färkkilä, M., Manns, M. P, Pares, A., Spengler, U., Stiess, M, Greinwald, R., Pröls, M, Wendum, D, Drebber, U, and Poupon, R.

Abstract

Background & Aims: In patients with primary biliary cholangitis (PBC) the utility of budesonide, a synthetic corticosteroid displaying high first-pass metabolism, is unresolved. In a placebo-controlled, double-blind trial, we evaluated the added-value of budesonide in those with PBC and ongoing risk of progressive disease despite ursodeoxycholic acid (UDCA). Methods: We evaluated 62 patients with PBC who had histologically confirmed hepatic inflammatory activity, according to the Ishak-score, and an alkaline phosphatase (ALP) >1.5x upper limit of normal (ULN), after at least 6 months of UDCA therapy. Participants were randomly assigned 2:1 to receive budesonide (9 mg/day) or placebo once daily, for 36 months, with UDCA treatment (12-16 mg/kg body weight/day) maintained. Primary efficacy was defined as improvement of liver histology with respect to inflammation and no progression of fibrosis. Secondary outcomes included changes in biochemical markers of liver injury. Results: Recruitment challenges resulted in a study underpowered compared to original intent. The primary histologic endpoint, comparing patients with paired biopsies only (n= 43), was not met (p>0.05). The proportion of patients with ALP

Published
2021

21. European Registry on Helicobacter pylori management (Hp-EuReg): Patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21 533 patients

Author

Nyssen, O. P., Bordin, D., Tepes, B., Perez-Aisa, A., Vaira, D., Caldas, M., Bujanda, L., Castro-Fernandez, M., Lerang, F., Leja, M., Rodrigo, L., Rokkas, T., Kupcinskas, L., Perez-Lasala, J., Jonaitis, L., Shvets, O., Gasbarrini, Antonio, Simsek, H., Axon, A. T. R., Buzas, G., Machado, J. C., Niv, Y., Boyanova, L., Goldis, A., Lamy, V., Tonkic, A., Przytulski, K., Beglinger, C., Venerito, M., Bytzer, P., Capelle, L., Milosavljevic, T., Milivojevic, V., Veijola, L., Molina-Infante, J., Vologzhanina, L., Fadeenko, G., Arino, I., Fiorini, G., Garre, A., Garrido, J., F Perez, C., Puig, I., Heluwaert, F., Megraud, F., O'Morain, C., Gisbert, J. P., Gasbarrini A. (ORCID:0000-0002-7278-4823), Nyssen, O. P., Bordin, D., Tepes, B., Perez-Aisa, A., Vaira, D., Caldas, M., Bujanda, L., Castro-Fernandez, M., Lerang, F., Leja, M., Rodrigo, L., Rokkas, T., Kupcinskas, L., Perez-Lasala, J., Jonaitis, L., Shvets, O., Gasbarrini, Antonio, Simsek, H., Axon, A. T. R., Buzas, G., Machado, J. C., Niv, Y., Boyanova, L., Goldis, A., Lamy, V., Tonkic, A., Przytulski, K., Beglinger, C., Venerito, M., Bytzer, P., Capelle, L., Milosavljevic, T., Milivojevic, V., Veijola, L., Molina-Infante, J., Vologzhanina, L., Fadeenko, G., Arino, I., Fiorini, G., Garre, A., Garrido, J., F Perez, C., Puig, I., Heluwaert, F., Megraud, F., O'Morain, C., Gisbert, J. P., and Gasbarrini A. (ORCID:0000-0002-7278-4823)

Abstract

Objective The best approach for Helicobacter pylori management remains unclear. An audit process is essential to ensure clinical practice is aligned with best standards of care. Design International multicentre prospective non-interventional registry starting in 2013 aimed to evaluate the decisions and outcomes in H. pylori management by European gastroenterologists. Patients were registered in an e-CRF by AEG-REDCap. Variables included demographics, previous eradication attempts, prescribed treatment, adverse events and outcomes. Data monitoring was performed to ensure data quality. Time-trend and geographical analyses were performed. Results 30 394 patients from 27 European countries were evaluated and 21 533 (78%) first-line empirical H. pylori treatments were included for analysis. Pretreatment resistance rates were 23% to clarithromycin, 32% to metronidazole and 13% to both. Triple therapy with amoxicillin and clarithromycin was most commonly prescribed (39%), achieving 81.5% modified intention-to-treat eradication rate. Over 90% eradication was obtained only with 10-day bismuth quadruple or 14-day concomitant treatments. Longer treatment duration, higher acid inhibition and compliance were associated with higher eradication rates. Time-trend analysis showed a region-dependent shift in prescriptions including abandoning triple therapies, using higher acid-inhibition and longer treatments, which was associated with an overall effectiveness increase (84%-90%). Conclusion Management of H. pylori infection by European gastroenterologists is heterogeneous, suboptimal and discrepant with current recommendations. Only quadruple therapies lasting at least 10 days are able to achieve over 90% eradication rates. European recommendations are being slowly and heterogeneously incorporated into routine clinical practice, which was associated with a corresponding increase in effectiveness.

Published
2021

24. East–West gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort

Author

Burisch, J, Pedersen, N, Čuković-Čavka, S, Brinar, M, Kaimakliotis, I, Duricova, D, Shonová, O, Vind, I, Avnstrøm, S, Thorsgaard, N, Andersen, V, Krabbe, S, Dahlerup, J F, Salupere, R, Nielsen, K R, Olsen, J, Manninen, P, Collin, P, Tsianos, E V, Katsanos, K H, Ladefoged, K, Lakatos, L, Björnsson, E, Ragnarsson, G, Bailey, Y, Odes, S, Schwartz, D, Martinato, M, Lupinacci, G, Milla, M, De Padova, A, DʼIncà, R, Beltrami, M, Kupcinskas, L, Kiudelis, G, Turcan, S, Tighineanu, O, Mihu, I, Magro, F, Barros, L F, Goldis, A, Lazar, D, Belousova, E, Nikulina, I, Hernandez, V, Martinez-Ares, D, Almer, S, Zhulina, Y, Halfvarson, J, Arebi, N, Sebastian, S, Lakatos, P L, Langholz, E, and Munkholm, P

Published
2014
Full Text
View/download PDF

25. Impact of Helicobacter pylori clarithromycin resistance on the treatment effectiveness: data of the European registry on H. pylori management (HP- EUREG)

Author

Bujanda L., Nyssen O.P., Cosme A., Bordin D.S., Tepeš B., Pere-Aisa A., Vaira D., Caldas Álvarez M., Castro-Fernandez M., Lerang F., Leja M., Rodrigo L., Rokkas T., Kupcinskas L., Perez-Lasala J., Jonaitis L., Shvets O., Gasbarrini A., Simsek H., Axon A.T.R., Buzas G.M., Machado J.C., Niv Y., Boyanova L., Goldis A., Lamy V., Tonkić Ante, Marlicz W., Beglinger C., Venerito M., Bytzer P., Capelle L.G., Milosavljevic T., Veijola L.I., Molina Infante J., Vologhzanina L., Fadeenko G., Ariño I., Fiorini G., Resina E., Muñoz R., Puig I., Megraud F., O’ Morain C., Gisbert J.P.

Subjects
Helicobacter pylori, clarithromycin, resistance
Abstract

Introduction: Antibiotic resistance is the major factor affecting our ability to cure Helicobacter pylori infection. Quadruple therapy is currently recommended ; however, triple therapy with two antibiotics may be sufficient in those patients without clarithromycin resistance. Aims & Methods: To evaluate the effectiveness of the treatments according to the clarithromycin H. pylori resistance in Europe. International multicenter prospective non-interventional European Registry on H. pylori Management (Hp-EuReg) aiming to evaluate the decisions and outcomes of H. pylori infection. Infected adult patients diagnosed with culture registered at AEG-REDCap e- CRF from 2013 to 2019. Per-protocol (PP) analysis was performed based on the presence or absence of clarithromycin bacterial resistance. Results: Overall, 5, 036 patients were included: 1, 747 (35%) were resistant and 3, 289 (65%) sensitive to clarithromycin. The overall eradication rate was higher in clarithromycin-susceptible patients (91% vs. 84% ; p< 0.001). Triple therapy with a PPI, clarithromycin and amoxicillin achieved over 90% eradication rates in clarithromycin- susceptible patients. However, in those with clarithromycin- resistance, optimal effectiveness was only achieved when treated with quadruple therapy with a PPI, clarithromycin, amoxicillin and bismuth. Conclusion: Classic triple therapy with a PPI, clarithromycin and amoxicillin achieves optimal results (>90%) in patients susceptible to clarithromycin. However, when clarithromycin resistance is unknown, quadruple therapy with a PPI, clarithromycin, amoxicillin and bismuth may be a better treatment option.

Published
2020

26. Helicobacter pylori antibiotic resistance: data from the European registry on H. pylori management (HP-EUREG)

Author

Bujanda L., Nyssen O.P., Cosme A., Bordin D.S., Tepeš B., Pere-Aisa A., Vaira D., Caldas Álvarez M., Castro-Fernandez M., Lerang F., Leja M., Rodrigo L., Rokkas T., Kupcinskas L., Perez-Lasala J., Jonaitis L., Shvets O., Gasbarrini A., Simsek H., Axon A.T.R., Buzas G.M., Machado J.C., Niv Y., Boyanova L., Goldis A., Lamy V., Tonkić Ante, Marlicz W., Beglinger C., Venerito M., Bytzer P., Capelle L.G., Milosavljevic T., Veijola L.I., Molina Infante J., Vologhzanina L., Fadeenko G., Ariño I., Fiorini G., Resina E., Muñoz R., Puig I., Megraud F., O’ Morain C., Gisbert J.P.

Subjects
Helicobacter pylori, antibiotic resistance
Abstract

Introduction: Antibiotic resistance is the major factor affecting our ability to cure Helicobacter pylori infection. Understanding the different H. pylori antibiotic resistances could be the key to improve treatment effectiveness. Aims & Methods: To evaluate the H. pylori antibiotic resistance both prior and after one or several eradication treatments, in order to provide the most appropriate recommendations for the eradication of H. pylori. International multicenter prospective non-interventional European Regis-try on H. pylori Management (Hp- EuReg) aiming to evaluate the decisions and outcomes of H. pylori infection by European gastroenterologists. Infected adult patients diagnosed with culture and with a result of the antibiotic resistance test registered at AEG- REDCap e-CRF from 2013 to 2019. Per-protocol (PP) analysis was performed. The antibiotic bacterial resistances were described by treatment line. Results: A total of 32, 447 patients were included, and culture was performed in 3, 474 (11%). In naïve patients, 21% reported single clarithromycin resistance, and 11% dual (clarithromycin and metronidazole) resistance. Antibiotic resistance increased markedly from the first treatment, reaching over 37% dual resistance in second-line treatment. Conclusion: In Europe, culture testing to determine antibiotic resistance against H. pylori is scarce. H. pylori single clarithromycin resistance remains high (>15%) in all treatment lines, and greater than 20% in naïve patients. Dual or triple resistances are frequent and increase remarkably after the first treatment failure. Resistance to amoxicillin or tetracycline is exceptional.

Published
2020

27. Antibiotic resistance trends of Helicobacter pylori naïve patients in the period 2013-2019: analysis of the European registry on H. pylori management (HP-EUREG)

Author

Bujanda L., Nyssen O.P., Cosme A., Bordin D.S., Tepeš B., Pere-Aisa A., Vaira D., Caldas Álvarez M., Castro-Fernandez M., Lerang F., Leja M., Rodrigo L., Rokkas T., Kupcinskas L., Perez-Lasala J., Jonaitis L., Shvets O., Gasbarrini A., Simsek H., Axon A.T.R., Buzas G.M., Machado J.C., Niv Y., Boyanova L., Goldis A., Lamy V., Tonkić Ante, Marlicz W., Beglinger C., Venerito M., Bytzer P., Capelle L.G., Milosavljevic T., Veijola L.I., Molina Infante J., Vologhzanina L., Fadeenko G., Ariño I., Fiorini G., Resinas E., Muñoz R., Puig I., Megraud F., O’ Morain C., Gisbert J.P.

Subjects
Helicobacter pylori, antibiotic resistance
Abstract

Introduction: Bacterial antibiotic resistance changes over time based on multiple factors. It is essential to study these trends to apply preventive strategies to help reducing such resistances.Aims & Methods: To conduct a time-trend analysis of the antibiotic resistance to H. pylori infection in the European Registry on H. pylori (Hp-EuReg). International multicenter prospective non- interventional European Registry on H. pylori Management (Hp-EuReg) aiming to evaluate the decisions and outcomes of H. pylori infection by European gastroenterologists. All infected adult patients diagnosed with culture and with a result of the antibiotic resistance test were registered at AEG-REDCap e-CRF from 2013 to 2019.Results: A total of 32, 447 patients were included, and culture was performed in 3, 474 (11%), where 2, 483 näive patients were included for analysis. Resistance to at least one antibiotic was described in 57% of the patients. Resistance to metronidazole (27%) was most frequent, whereas resistance to tetracycline and amoxicillin was below 1%. Clarithromycin resistance remained above 15% throughout the studied years. A significant decrease in the metronidazole resistance rate was observed between 2013 (38%) and 2018 (21%).Conclusion: In naïve patients, resistance to clarithromycin remained above 15% in the period 2013-2019. A progressive decrease in metronidazole resistance was observed. No increasing or decreasing trend was observed in the bacterial resistance to other antibiotics.

Published
2020

28. Helicobacter pylori first-line and rescue treatments in patients allergic to penicillin: Experience from the European Registry on H pylori management (Hp-EuReg)

Author

Nyssen, O. P., Perez-Aisa, A., Tepes, B., Rodrigo-Saez, L., Romero, P. M., Lucendo, A., Castro-Fernandez, M., Phull, P., Barrio, J., Bujanda, L., Ortuno, J., Areia, M., Brglez Jurecic, N., Huguet, J. M., Alcaide, N., Voynovan, I., Maria Botargues Bote, J., Modolell, I., Perez Lasala, J., Arino, I., Jonaitis, L., Dominguez-Cajal, M., Buzas, G., Lerang, F., Perona, M., Bordin, D., Axon, T., Gasbarrini, Antonio, Marcos Pinto, R., Niv, Y., Kupcinskas, L., Tonkic, A., Leja, M., Rokkas, T., Boyanova, L., Shvets, O., Venerito, M., Bytzer, P., Goldis, A., Simsek, I., Lamy, V., Przytulski, K., Kunovsky, L., Capelle, L., Milosavljevic, T., Caldas, M., Garre, A., Megraud, F., O'Morain, C., Gisbert, J. P., Hinojosa, J., Fernandez, N., Molina Infante, J., Alonso Galan, H., Di Maira, T., Alves, S. I., Saraiva, S., Elvas, L., Brito, D., Teresa Cadime, A., Lampic, P., Gruncic, A., Leban, V., Ferrer, L., Fernandez Salazar, L., Lanas, A., Kristensen, V., Brackmann, S., Delchier, J. C., Anton, C., Gomez Rodriguez, B. J., Pellicano, R., Boltin, D., and Gastroenterology & Hepatology

Subjects
medicine.medical_specialty, Allergy, Settore MED/12 - GASTROENTEROLOGIA, allergic, Penicillins, Gastroenterology, Helicobacter Infections, Drug Hypersensitivity, 03 medical and health sciences, 0302 clinical medicine, Levofloxacin, Metronidazole, Clarithromycin, Internal medicine, bismuth, medicine, Humans, Prospective Studies, Registries, Adverse effect, levofloxacin, biology, Helicobacter pylori, business.industry, Settore MED/09 - MEDICINA INTERNA, allergy, clarithromycin, penicillin, Proton Pump Inhibitors, General Medicine, Tetracycline, biology.organism_classification, medicine.disease, Anti-Bacterial Agents, 3. Good health, Penicillin, Regimen, Infectious Diseases, 030220 oncology & carcinogenesis, Drug Therapy, Combination, 030211 gastroenterology & hepatology, business, medicine.drug
Abstract

Background Experience in Helicobacter pylori eradication treatment of patients allergic to penicillin is very scarce. A triple combination with a PPI, clarithromycin (C), and metronidazole (M) is often prescribed as the first option, although more recently the use of a quadruple therapy with PPI, bismuth (B), tetracycline (T), and M has been recommended. Aim To evaluate the efficacy and safety of first-line and rescue treatments in patients allergic to penicillin in the "European Registry of H pylori management" (Hp-EuReg). Methods A systematic prospective registry of the clinical practice of European gastroenterologists (27 countries, 300 investigators) on the management of H pylori infection. An e-CRF was created on AEG-REDCap. Patients with penicillin allergy were analyzed until June 2019. Results One-thousand eighty-four patients allergic to penicillin were analyzed. The most frequently prescribed first-line treatments were as follows: PPI + C + M (n = 285) and PPI + B + T + M (classic or Pylera(R); n = 250). In first line, the efficacy of PPI + C + M was 69%, while PPI + B + T + M reached 91% (P < .001). In second line, after the failure of PPI + C + M, two rescue options showed similar efficacy: PPI + B + T + M (78%) and PPI + C + levofloxacin (L) (71%) (P > .05). In third line, after the failure of PPI + C + M and PPI + C + L, PPI + B + T + M was successful in 75% of cases. Conclusion In patients allergic to penicillin, a triple combination with PPI + C + M should not be generally recommended as a first-line treatment, while a quadruple regimen with PPI + B + T + M seems to be a better option. As a rescue treatment, this quadruple regimen (if not previously prescribed) or a triple regimen with PPI + C + L could be used but achieved suboptimal (

Published
2020

29. First line H. pylori eradication therapy in Europe: results from 24,882 cases of the European registry on H. pylori management (HP-EUREG)

Author

Nyssen O.P., Bordin D.S., Tepeš B., Perez Aisa M.Á., Caldas Álvarez M., Bujanda Fernández de Piérola L., Pabon Carrasco M., Castro Fernandez M., Lerang F., Leja M., Rokkas T., Kupcinskas L., Jonaitis L., Shvets O., Gasbarrini A., Axon A., Şimşek H., Buzás G.M., Machado J.C.L., Niv Y., Boyanova L., Rodrigo L., Perez-Lasala J., Goldis E.-A., Lamy V., Tonkić Ante, Przytulski K., Beglinger C., Venerito M., Bytzer P., Capelle L., Milivojević V., Veijola L., Molina Infante J., Vologzhanina L., Dino V., Fadeenko G., Ariño Pérez I., Fiorini G., Garre A., Keko-Huerga A., Heluwaert F., Garrido J., Fernandez Perez C., Puig I., Megraud F., O’Morain C., Gisbert J.P.

Subjects
Helicobacter pylori, eradication therapy
Abstract

Introduction: The best approach for Helicobacter pylori management remains unclear. An audit process is essential to ensure clinical practice is aligned with best standards of care.Aims & Methods: International multicentre prospective non-interventional registry starting in 2013 aimed to evaluate the decisions and outcomes in H. pylori management by European gastroenterologists. Patients were registered in an e-CRF by AEG-REDCap up to April 2020. Variables included: demographics, previous eradication attempts, prescribed treatment, adverse events, and outcomes. Modified intention-to-treat (mITT) and per-protocol (PP) analyses were performed and data were subject to quality review to ensure information reliability.Results: In total 36, 319 patients from 29 European countries were evaluated and 24, 882 (70%) first-line empirical H. pylori treatments were included for analysis. Triple therapy with amoxicillin and clarithromycin was most commonly prescribed (40%), followed by concomitant treatment (19%) and bismuth quadruple (Pylera®) (10%) achieving 83%, 91% and 95% mITT eradication rate, respectively. Over 90% effectiveness was obtained only with 10 and 14-day bismuth quadruple or 14-day concomitant treatment (Table). Longer treatment duration, higher acid inhibition and compliance were associated with higher eradication rates.Conclusion: Management of H. pylori infection by European gastroenterologists is heterogeneous. Only quadruple therapies lasting at least ten days are able to achieve over 90% eradication rates.

Published
2020

33. Randomised clinical trial: the efficacy and safety of propionyl-l-carnitine therapy in patients with ulcerative colitis receiving stable oral treatment

Author

Mikhailova, T. L., Sishkova, E., Poniewierka, E., Zhidkov, K. P., Bakulin, I. G., Kupcinskas, L., Lesniakowski, K., Grinevich, V. B., Malecka-Panas, E., Ardizzone, S., D’Arienzo, A., Valpiani, D., Koch, M., Denapiene, G., Vago, G., Fociani, P., Zerbi, P., Ceracchi, M., Camerini, R., and Gasbarrini, G.

Published
2011
Full Text
View/download PDF

37. IBD risk loci are enriched in multigenic regulatory modules encompassing putative causative genes

Author

Momozawa, Y, Dmitrieva, J, Theatre, E, Deffontaine, V, Rahmouni, S, Charloteaux, B, Crins, F, Docampo, E, Elansary, M, Gori, AS, Lecut, C, Mariman, R, Mni, M, Oury, C, Altukhov, I, Alexeev, D, Aulchenko, Y, Amininejad, L, Bouma, G, Hoentjen, F, Lowenberg, M, Oldenburg, B, Pierik, MJ, de Jong, AE, van der Woude, C.J., Visschedijk, MC, Lathrop, M, Hugot, JP, Weersma, RK, Vos, M, Franchimont, D, Vermeire, S, Kubo, M, Louis, E, Georges, M, Abraham, C, Achkar, JP, Ahmad, T, Ananthakrishnan, AN, Andersen, V, Anderson, CA, Andrews, JM, Annese, V, Aumais, G, Baidoo, L, Baldassano, RN, Bampton, PA, Barclay, M, Barrett, JC, Bayless, TM, Bethge, J, Bitton, A, Boucher, G, Brand, S, Brandt, B, Brant, SR, Buning, C, Chew, A, Cho, JH, Cleynen, I, Cohain, A, Croft, A, Daly, MJ, D'Amato, M, Danese, S, Jong, D, Denapiene, G, Denson, LA, Devaney, KL, Dewit, O, D'Inca, R, Dubinsky, M, Duerr, RH, Edwards, C, Ellinghaus, D, Essers, J, Ferguson, LR, Festen, EA, Fleshner, P, Florin, T, Franke, A, Fransen, K, Gearry, R, Gieger, C, Glas, J, Goyette, P, Green, T, Griffiths, AM, Guthery, SL, Hakonarson, H, Halfvarson, J, Hanigan, K, Haritunians, T, de Hart, A, Hawkey, C, Hayward, NK, Hedl, M, Henderson, P, Hu, XH, Huang, HL, Hui, KY, Imielinski, M, Ippoliti, A, Jonaitis, L, Jostins, L, Karlsen, TH, Kennedy, NA, Khan, MA, Kiudelis, G, Krishnaprasad, K, Kugathasan, S, Kupcinskas, L, Latiano, A, Laukens, D, Lawrance, IC, Lee, JC, Lees, CW, Leja, M, van Limbergen, J, Lionetti, P, Liu, JZ, Mahy, G, Mansfield, J, Massey, D, Mathew, CG, McGovern, DPB, Milgrom, R, Mitrovic, M, Montgomery, GW, Mowat, C, Newman, W, Ng, A, Ng, SC, Ng, SME, Nikolaus, S, Ning, K, Nothen, M, Oikonomou, I, Palmieri, O, Parkes, M, Phillips, A, Ponsioen, CY, Potocnik, U, Prescott, NJ, Proctor, DD, Radford-Smith, G, Rahier, JF, Raychaudhuri, S, Regueiro, M, Rieder, F, Rioux, JD, Ripke, S, Roberts, R, Russell, RK, Sanderson, JD, Sans, M, Satsangi, J, Schadt, EE, Schreiber, S, Schulte, D, Schumm, LP, Scott, R, Seielstad, M, Sharma, Y, Silverberg, MS, Simms, LA, Skieceviciene, J, Spain, SL, Steinhart, AH, Stempak, JM, Stronati, L, Sventoraityte, J, Targan, SR, Taylor, KM, Velde, A, Torkvist, L, Tremelling, M, van Sommeren, S, Vasiliauskas, E, Verspaget, HW, Walters, T, Wang, K, Wang, MH, Wei, Z, Whiteman, D, Wijmenga, C, Wilson, DC, Winkelmann, J, Xavier, RJ, Zhang, B, Zhang, CK, Zhang, H, Zhang, W, Zhao, HY, Zhao, ZZ, Momozawa, Y, Dmitrieva, J, Theatre, E, Deffontaine, V, Rahmouni, S, Charloteaux, B, Crins, F, Docampo, E, Elansary, M, Gori, A, Lecut, C, Mariman, R, Mni, M, Oury, C, Altukhov, I, Alexeev, D, Aulchenko, Y, Amininejad, L, Bouma, G, Hoentjen, F, Lowenberg, M, Oldenburg, B, Pierik, Mj, vander Meulen-de Jong, Ae, van der Woude, Cj, Visschedijk, Mc, Lathrop, M, Hugot, Jp, Weersma, Rk, De Vos, M, Franchimont, D, Vermeire, S, Kubo, M, Louis, E, Georges, M, Abraham, C, Achkar, Jp, Ahmad, T, Ananthakrishnan, An, Andersen, V, Anderson, Ca, Andrews, Jm, Annese, V, Aumais, G, Baidoo, L, Baldassano, Rn, Bampton, Pa, Barclay, M, Barrett, Jc, Bayless, Tm, Bethge, J, Bitton, A, Boucher, G, Brand, S, Brandt, B, Brant, Sr, Buning, C, Chew, A, Cho, Jh, Cleynen, I, Cohain, A, Croft, A, Daly, Mj, D'Amato, M, Danese, S, De Jong, D, Denapiene, G, Denson, La, Devaney, Kl, Dewit, O, D'Inca, R, Dubinsky, M, Duerr, Rh, Edwards, C, Ellinghaus, D, Essers, J, Ferguson, Lr, Festen, Ea, Fleshner, P, Florin, T, Franke, A, Fransen, K, Gearry, R, Gieger, C, Glas, J, Goyette, P, Green, T, Griffiths, Am, Guthery, Sl, Hakonarson, H, Halfvarson, J, Hanigan, K, Haritunians, T, Hart, A, Hawkey, C, Hayward, Nk, Hedl, M, Henderson, P, Hu, Xh, Huang, Hl, Hui, Ky, Imielinski, M, Ippoliti, A, Jonaitis, L, Jostins, L, Karlsen, Th, Kennedy, Na, Khan, Ma, Kiudelis, G, Krishnaprasad, K, Kugathasan, S, Kupcinskas, L, Latiano, A, Laukens, D, Lawrance, Ic, Lee, Jc, Lees, Cw, Leja, M, Van Limbergen, J, Lionetti, P, Liu, Jz, Mahy, G, Mansfield, J, Massey, D, Mathew, Cg, Mcgovern, Dpb, Milgrom, R, Mitrovic, M, Montgomery, Gw, Mowat, C, Newman, W, Ng, A, Ng, Sc, Ng, Sme, Nikolaus, S, Ning, K, Nothen, M, Oikonomou, I, Palmieri, O, Parkes, M, Phillips, A, Ponsioen, Cy, Potocnik, U, Prescott, Nj, Proctor, Dd, Radford-Smith, G, Rahier, Jf, Raychaudhuri, S, Regueiro, M, Rieder, F, Rioux, Jd, Ripke, S, Roberts, R, Russell, Rk, Sanderson, Jd, Sans, M, Satsangi, J, Schadt, Ee, Schreiber, S, Schulte, D, Schumm, Lp, Scott, R, Seielstad, M, Sharma, Y, Silverberg, M, Simms, La, Skieceviciene, J, Spain, Sl, Steinhart, Ah, Stempak, Jm, Stronati, L, Sventoraityte, J, Targan, Sr, Taylor, Km, ter Velde, A, Torkvist, L, Tremelling, M, van Sommeren, S, Vasiliauskas, E, Verspaget, Hw, Walters, T, Wang, K, Wang, Mh, Wei, Z, Whiteman, D, Wijmenga, C, Wilson, Dc, Winkelmann, J, Xavier, Rj, Zhang, B, Zhang, Ck, Zhang, H, Zhang, W, Zhao, Hy, Zhao, Zz, Gastroenterology & Hepatology, UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie, and UCL - (MGD) Service de gastro-entérologie

Subjects
Adult, Male, Multifactorial Inheritance, QUANTITATIVE TRAIT LOCUS, Genotype, SEQUENCING DATA, Quantitative Trait Loci, SUSCEPTIBILITY, Polymorphism, Single Nucleotide, Article, Cohort Studies, CODING VARIANTS, Crohn Disease, 80 and over, Journal Article, Medicine and Health Sciences, LOCUS, Humans, Genetic Predisposition to Disease, Polymorphism, GENOME-WIDE ASSOCIATION, Genetic Association Studies, Aged, Aged, 80 and over, Science & Technology, Female, Gene Expression Profiling, Inflammatory Bowel Diseases, Middle Aged, Sequence Analysis, DNA, COMPLEX TRAITS, Biology and Life Sciences, Single Nucleotide, DNA, CROHNS-DISEASE, Multidisciplinary Sciences, QUANTITATIVE TRAIT, RARE VARIANTS, Science & Technology - Other Topics, LOW-FREQUENCY, Sequence Analysis, INFLAMMATORY-BOWEL-DISEASE
Abstract

GWAS have identified >200 risk loci for Inflammatory Bowel Disease (IBD). The majority of disease associations are known to be driven by regulatory variants. To identify the putative causative genes that are perturbed by these variants, we generate a large transcriptome data set (nine disease-relevant cell types) and identify 23,650 cis-eQTL. We show that these are determined by ∼9720 regulatory modules, of which ∼3000 operate in multiple tissues and ∼970 on multiple genes. We identify regulatory modules that drive the disease association for 63 of the 200 risk loci, and show that these are enriched in multigenic modules. Based on these analyses, we resequence 45 of the corresponding 100 candidate genes in 6600 Crohn disease (CD) cases and 5500 controls, and show with burden tests that they include likely causative genes. Our analyses indicate that ≥10-fold larger sample sizes will be required to demonstrate the causality of individual genes using this approach., Most of the more than 200 known genetic risk loci for inflammatory bowel disease (IBD) reside in regulatory regions. Here, the authors provide eQTL datasets for six circulating immune cell types and ileal, colonic and rectal biopsies to map regulatory modules and identify potential causative genes for IBD.

Published
2018

41. Efficacy of Per-oral Methylene Blue Formulation for Screening Colonoscopy

Author

Repici, A., Wallace, M.B., East, J.E., Sharma, P., Ramirez, F.C., Bruining, D.H., Young, M., Gatof, D., Canto, M.I., Marcon, N., Cannizzaro, R., Kiesslich, R., Rutter, M., Dekker, E., Siersema, P.D., Spaander, M., Kupcinskas, L., Jonaitis, L., Bisschops, R., Radaelli, F., Bhandari, P., Wilson, A., Early, D., Gupta, N., Vieth, M., Lauwers, G.Y., Rossini, M., Hassan, C., Repici, A., Wallace, M.B., East, J.E., Sharma, P., Ramirez, F.C., Bruining, D.H., Young, M., Gatof, D., Canto, M.I., Marcon, N., Cannizzaro, R., Kiesslich, R., Rutter, M., Dekker, E., Siersema, P.D., Spaander, M., Kupcinskas, L., Jonaitis, L., Bisschops, R., Radaelli, F., Bhandari, P., Wilson, A., Early, D., Gupta, N., Vieth, M., Lauwers, G.Y., Rossini, M., and Hassan, C.

Abstract

Contains fulltext : 205156.pdf (publisher's version ) (Closed access), BACKGROUND & AIMS: Topically applied methylene blue dye chromoendoscopy is effective in improving detection of colorectal neoplasia. When combined with a pH- and time-dependent multimatrix structure, a per-oral methylene blue formulation (MB-MMX) can be delivered directly to the colorectal mucosa. METHODS: We performed a phase 3 study of 1205 patients scheduled for colorectal cancer screening or surveillance colonoscopies (50-75 years old) at 20 sites in Europe and the United States, from December 2013 through October 2016. Patients were randomly assigned to groups given 200 mg MB-MMX, placebo, or 100 mg MB-MMX (ratio of 2:2:1). The 100-mg MB-MMX group was included for masking purposes. MB-MMX and placebo tablets were administered with a 4-L polyethylene glycol-based bowel preparation. The patients then underwent colonoscopy by an experienced endoscopist with centralized double-reading. The primary endpoint was the proportion of patients with 1 adenoma or carcinoma (adenoma detection rate [ADR]). We calculated odds ratios (ORs) and 95% confidence intervals (CIs) for differences in detection between the 200-mg MB-MMX and placebo groups. False-positive (resection rate for non-neoplastic polyps) and adverse events were assessed as secondary endpoints. RESULTS: The ADR was higher for the MB-MMX group (273 of 485 patients, 56.29%) than the placebo group (229 of 479 patients, 47.81%) (OR 1.46; 95% CI 1.09-1.96). The proportion of patients with nonpolypoid lesions was higher in the MB-MMX group (213 of 485 patients, 43.92%) than the placebo group (168 of 479 patients, 35.07%) (OR 1.66; 95% CI 1.21-2.26). The proportion of patients with adenomas

Published
2019

42. Association of adverse perinatal outcomes of intrahepatic cholestasis of pregnancy with biochemical markers

Author

Ovadia, C., Seed, P.T. (P.), Sklavounos, A., Geenes, V., Di Illio, C., Chambers, J. (John), Kohari, K., Bacq, Y., Bozkurt, N., Brun-Furrer, R., Bull, I.D. (Ian), Estiu, M.C., Grymowicz, M., Gunaydin, B., Hague, W.M., Haslinger, C., Hu, Y. (Yu), Kawakita, T., Kebapcilar, A.G., Kebapcilar, L., Kondrackiene, J. (Jurate), Koster, M.P.H., Kowalska-Kanka, A., Kupcinskas, L. (Limas), Lee, R.H., Locatelli, A. (Alberta), Macias, R.I.R., Marschall, H.-U., Oudijk, M.A. (Martijn), Raz, Y., Rimon, E., Shan, D., Shao, Y, Tribe, R., Tripodi, V., Abide, C.Y., Yenidede, I., Thornton, J.G. (Jim), Chappell, LC, Williamson, C. (Catherine), Ovadia, C., Seed, P.T. (P.), Sklavounos, A., Geenes, V., Di Illio, C., Chambers, J. (John), Kohari, K., Bacq, Y., Bozkurt, N., Brun-Furrer, R., Bull, I.D. (Ian), Estiu, M.C., Grymowicz, M., Gunaydin, B., Hague, W.M., Haslinger, C., Hu, Y. (Yu), Kawakita, T., Kebapcilar, A.G., Kebapcilar, L., Kondrackiene, J. (Jurate), Koster, M.P.H., Kowalska-Kanka, A., Kupcinskas, L. (Limas), Lee, R.H., Locatelli, A. (Alberta), Macias, R.I.R., Marschall, H.-U., Oudijk, M.A. (Martijn), Raz, Y., Rimon, E., Shan, D., Shao, Y, Tribe, R., Tripodi, V., Abide, C.Y., Yenidede, I., Thornton, J.G. (Jim), Chappell, LC, and Williamson, C. (Catherine)

Abstract

__Background__ Intrahepatic cholestasis of pregnancy is associated with adverse perinatal outcomes, but the association with the concentration of specific biochemical markers is unclear. We aimed to quantify the adverse perinatal effects of intrahepatic cholestasis of pregnancy in women with increased serum bile acid concentrations and determine whether elevated bile acid concentrations were associated with the risk of stillbirth and preterm birth. __Methods__ We did a systematic review by searching PubMed, Web of Science, and Embase databases for studies published from database inception to June 1, 2018, reporting perinatal outcomes for women with intrahepatic cholestasis of pregnancy when serum bile acid concentrations were available. Inclusion criteria were studies defining intrahepatic cholestasis of pregnancy based upon pruritus and elevated serum bile acid concentrations, with or without raised liver aminotransferase concentrations. Eligible studies were case-control, cohort, and populationbased studies, and randomised controlled trials, with at least 30 participants, and that reported bile acid concentrations and perinatal outcomes. Studies at potential higher risk of reporter bias were excluded, including case reports, studies not comprising cohorts, or successive cases seen in a unit; we also excluded studies with high risk of bias from groups selected (eg, a subgroup of babies with poor outcomes were explicitly excluded), conference abstracts, and Letters to the Editor without clear peer review. We also included unpublished data from two UK hospitals. We did a random effects meta-analysis to determine risk of adverse perinatal outcomes. Aggregate data for maternal and perinatal outcomes were extracted from case-control studies, and individual patient data (IPD) were requested from study authors for all types of study (as no control group was required for the IPD analysis) to assess associations between biochemical markers and adverse outcomes using logisti

Published
2019
Full Text
View/download PDF

43. Cost analysis in a prospective European population-based inception cohort : is there a cost-saving effect of biological therapy?

Author

Burisch, J., Vardi, H., Schwartz, D., Krznaric, Z., Lakatos, P. L., Fumery, M., Kupcinskas, L., Magro, F., Belousova, E., Oksanen, P., Arebi, N., Langholz, E., Turcan, S., D'Inca, R., Hernandez, V., Valpiani, D., Vegh, Z., Giannotta, M., Katsanos, K. H., Duricova, D., Nielsen, K. R., Kievit, H. A. L., Ellul, P., Salupere, R., Goldis, A., Kaimakliotis, I., Pedersen, N., Andersen, V., Halfvarson, Jonas, Sebastian, S., Dahlerup, J. F., Munkholm, P., Odes, S., Burisch, J., Vardi, H., Schwartz, D., Krznaric, Z., Lakatos, P. L., Fumery, M., Kupcinskas, L., Magro, F., Belousova, E., Oksanen, P., Arebi, N., Langholz, E., Turcan, S., D'Inca, R., Hernandez, V., Valpiani, D., Vegh, Z., Giannotta, M., Katsanos, K. H., Duricova, D., Nielsen, K. R., Kievit, H. A. L., Ellul, P., Salupere, R., Goldis, A., Kaimakliotis, I., Pedersen, N., Andersen, V., Halfvarson, Jonas, Sebastian, S., Dahlerup, J. F., Munkholm, P., and Odes, S.

Published
2019
Full Text
View/download PDF

50. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report

Author

Malfertheiner, P., Megraud, F., O'Morain, C. A., Gisbert, J. P., Kuipers, E. J., Axon, A. T., Bazzoli, F., Gasbarrini, A., Atherton, J., Graham, D. Y., Hunt, R., Moayyedi, P., Rokkas, T., Rugge, M., Selgrad, M., Suerbaum, S., Sugano, K., El-Omar, E. M., Agreus, L., Andersen, L. P., Axon, A., Coelho, L., Delchier, J. C., Di Mario, F., Dinis-Ribeiro, M., El-Omar, E., Fischbach, W., Flahou, B., Fock, K. M., Gasbarrini, G., Gensini, G., Gisbert, J., Goh, K. L., Herrero, R., Kupcinskas, L., Lanas, A., Leja, M., Machado, J. C., Mahachai, V., Milosavljevic, T., Molina-Infante, J., Niv, Y., O'Morain, C., Ristimaki, A., Tepes, B., Vaira, D., Vieth, M., You, W., Gastroenterology & Hepatology, Malfertheiner, P., Megraud, F., O'Morain, C.A., Gisbert, J.P., Kuipers, E.J., Axon, A.T., Bazzoli, F., Gasbarrini, A., Atherton, J., Graham, D.Y., Hunt, R., Moayyedi, P., Rokkas, T., Rugge, M., Selgrad, M., Suerbaum, S., Sugano, K., El-Omar, E.M., Agreus, L., Andersen, L.P., Axon, A., Coelho, L., Delchier, J.C., Di Mario, F., Dinis-Ribeiro, M., El-Omar, E., Fischbach, W., Flahou, B., Fock, K.M., Gasbarrini, G., Gensini, G., Gisbert, J., Goh, K.L., Herrero, R., Kupcinskas, L., Lanas, A., Leja, M., Machado, J.C., Mahachai, V., Milosavljevic, T., Molina-Infante, J., Niv, Y., O'Morain, C., Ristimaki, A., Tepes, B., Vaira, D., Vieth, M., and You, W.

Subjects
Helicobacter pylori infection, Proton Pump Inhibitor, Gastroenterology, 0302 clinical medicine, Fluoroquinolone, Risk Factors, HELICOBACTER THERAPY, Medicine, Early Detection of Cancer, Evidence-Based Medicine, biology, Microbial Sensitivity Test, Stomach, Consensus conference, Anti-Bacterial Agents, Nitroimidazoles, 030220 oncology & carcinogenesis, Practice Guidelines as Topic, 030211 gastroenterology & hepatology, Drug Therapy, Combination, Fluoroquinolones, Human, medicine.medical_specialty, Settore MED/12 - GASTROENTEROLOGIA, Microbial Sensitivity Tests, Helicobacter Infections, 03 medical and health sciences, Stomach Neoplasms, Stomach Neoplasm, Internal medicine, Clarithromycin, Clarithromycin resistance, Anti-Bacterial Agent, Drug Resistance, Bacterial, Gastroscopy, Humans, Dyspepsia, GASTRITIS, HELICOBACTER PYLORI, Helicobacter pylori, business.industry, Public health, Nitroimidazole, Risk Factor, Gastriti, Amoxicillin, Proton Pump Inhibitors, biology.organism_classification, Gastrointestinal Microbiome, Family medicine, business, Bismuth, Helicobacter Infection
Abstract

Important progress has been made in the management of Helicobacter pylori infection and in this fifth edition of the Maastricht Consensus Report, key aspects related to the clinical role of H. Pylori were re-evaluated in 2015. In the Maastricht V/Florence Consensus Conference, 43 experts from 24 countries examined new data related to H. pylori in five subdivided workshops: (1) Indications/ Associations, (2) Diagnosis, (3) Treatment, (4) Prevention/Public Health, (5) H. pylori and the Gastric Microbiota. The results of the individual workshops were presented to a final consensus voting that included all participants. Recommendations are provided on the basis of the best available evidence and relevance to the management of H. pylori infection in the various clinical scenarios.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results